Overview


According to FutureWise analysis the market for Capecitabine is expected to register a CAGR of 5.80% from 2023-2031.

Capecitabine is a chemotherapy drug that can be used to treat colorectal, breast, and stomach cancers. Capecitabine, a prodrug for fluorouracil has been created to treat tumor-selective fluoropyrimidine carbohydrates in tumor cells. Capecitabine can be taken orally daily to mimic continuous fluorouracil administration. The most common side effects are nausea, vomiting, diarrhea, and mouth ulcers. It is part of a class of medications known as antifolates. Capecitabine is used for the treatment of metastatic breast cancer. Capecitabine can also be used with chemotherapy drugs to treat early-stage breast carcinoma. Capecitabine can be administered before or after surgery (neoadjuvant treatment) to reduce the chance of cancer returning. Capecitabine, a prodrug, is selectively tumor-activated by fluorouracil (cytotoxic moiety) by thymidine phosphorylase. This enzyme is found in higher levels in tumors than in normal tissues and plasma.Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumor cells. Two mechanisms are involved in cell injury caused by these metabolites. To form the covalently bound ternary complex, FdUMP and N5-10-methylenetetrahydrofolate bind to thymidylate synthase (TS). This binding prevents the formation of thymidylate 2'-deaxyuridylate. Thymidylate, which is the necessary precursor to thymidine Triphosphate (DNA synthesis), can be inhibited by this binding. Secondly, nuclear transcriptal enzymes may mistakenly include FUTP instead of uridine triphosphate. This metabolic error can cause problems in RNA processing or protein synthesis by producing fraudulent RNA. Many hospitals offer a free information session on chemotherapy before you start your treatment. A nurse will discuss how, when and what side effects you can expect from your chemotherapy.

A nurse will explain how to manage side effects and give blood tests. Some people may also need an ECG (electrocardiogram), which is a simple test that measures your heart rhythm. Every person who is starting capecitabine should have a blood test to determine if there are any levels of DPD. To determine the right dose of chemotherapy, your height and weight will be measured. To make it easy for you to contact the right person if you have questions or concerns, you will be provided with numbers. Capecitabine comes in two strengths: 150mg and 500mg. To ensure you are getting the correct amount of Capecitabine each day, you will be instructed how many tablets to take. Capecitabine is used for colorectal cancers that have spread to other areas of the body. It can be administered before or after surgery (neoadjuvant treatment) along with a platinum-based chemotherapy drug called oxaliplatin. This is followed by another type of chemo called Irinotecan Hydrochloride. Capecitabine can be used to treat stomach cancers that have spread to other areas of the body. It can be administered before or after surgery (neoadjuvant treatment). To treat stomach cancers that are not surgically removed, Capecitabine can be used with fluorouracil and cisplatin.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Capecitabine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Capecitabine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Teva Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG (Genentech, Inc.)
  • Mylan N.V.
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Indication

  • Colorectal Cancer
  • Breast Cancer
  • Others

By Distribution Channel

  • Hospitals
  • Clinical Laboratories
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Capecitabine Market By Indication, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Capecitabine Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Capecitabine Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Capecitabine Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Capecitabine Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Colorectal Cancer
        2. Breast Cancer
        3. Others

  • 8.   Capecitabine Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinical Laboratories
        3. Others

  • 9.   North America Capecitabine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Capecitabine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Capecitabine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Capecitabine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Teva Pharmaceuticals, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. F. Hoffmann-La Roche AG (Genentech, Inc.)
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Mylan N.V.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Hikma Pharmaceuticals PLC
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Cipla Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients